, Tracking Stock Market Picks
Enter Symbol:
Panacos Pharmaceuticals, Inc. (PANC) [hlAlert]

Sector Perform

Panacos Pharmaceuticals, Inc. (PANC) rated Sector Perform with price target $1.50 by RBC Capital Mkts

Posted on: Wednesday,  Mar 5, 2008  9:25 AM ET by RBC Capital Mkts

Panacos Pharma (PANC) rated Sector
Perform with price target $1.50 by RBC Capital Mkts.

Panacos Pharmaceuticals, Inc. (Panacos) is a development-stage biotechnology company that seeks to develop next generation anti-infective products through the discovery and development of small-molecule oral drugs designed to treat human immunodeficiency virus (HIV) and other human viral diseases. The Company's lead product candidate, bevirimat, is an oral HIV drug candidate in Phase II clinical testing. Panacos has dosed over 485 patients and subjects with bevirimat and have seen a good safety and tolerability profile with no indication of a relationship between adverse events and drug levels. The Company has exclusive rights from University of North Carolina at Chapel Hill (UNC) to the United States patent claiming the chemical entity bevirimat. Panacos has an exclusive worldwide license with UNC for all indications.

RBC Capital Markets is an international corporate and investment bank that provides innovative solutions and a focused set of products and services to institutions, corporations, governments and high net worth clients around the world. With nearly 3,700 professional and support staff, we operate out of 75 offices in 15 countries and deliver our products and services through operations in Asia and Australasia, the UK and Europe and in every major North American city.
Stock Market Advice
Date/Time (ET)SymbolRatingTermPrice (*)Target
3/5/2008 9:25 AM Hold
0.90 1.50
as of 12/24/2008
1 Week up  300.00 %
1 Month down  -33.33 %
3 Months down  -42.85 %
1 YTD down  -71.42 %

(*) Stock Price at the time of the recommendation.
RSS Feed | |  Facebook |  Twitter |  Google Plus
Home | Terms of Use | Advertise | FAQ | Support Page | Contact Us | About Us | Privacy Policy